Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
暂无分享，去创建一个
A. Chanan-Khan | A. Roberts | P. Moreau | J. Leverson | A. Agarwal | C. Touzeau | J. Ross | T. Facon | W. Munasinghe | A. Salem | S. Enschede | R. Humerickhouse | D. Lebovic | Ming Zhu | David E. Darden | Lura Morris | S. Harrison